Incidence of cutaneous malignancy following the concomitant use of cyclosporine and narrowband UV-B phototherapy in patients with vitiligo
Clinical and Experimental Dermatology
Clinical Summary
View sourceWhat was studied
A nationwide population-based cohort study using the Korean National Health Insurance Service database evaluated the incidence of cutaneous malignancies in vitiligo patients treated with concomitant cyclosporine and narrowband UV‑B phototherapy.
Key findings
Concomitant cyclosporine plus narrowband UV‑B therapy may not significantly increase the incidence of cutaneous malignancies.
Clinical implications
For patients with vitiligo, combining cyclosporine with narrowband UV‑B may be oncologically safe according to this nationwide cohort.
Related Questions
Explore related topics and deepen your understanding
How does cyclosporine plus narrowband UV‑B compare with UV‑B alone for skin cancer risk in vitiligo?What duration and cumulative dose of narrowband UV‑B are linked to malignancy risk in vitiligo patients?Current guideline advice on combining systemic immunosuppressants with phototherapy for vitiligo